The Conversation (0)
The Moscow Institute of Physics and Technology Biopharmaceutical cluster “Northern” (BPCN@MIPT), the Wisconsin Technology Innovation Initiative, Inc. (Wi2) and ChemDiv Research Institute have signed an MOU to form a non-exclusive consortium developing innovative therapeutics aimed at improvement of human and animal health.
The Moscow Institute of Physics and Technology Biopharmaceutical cluster “Northern” (BPCN@MIPT), the Wisconsin Technology Innovation Initiative, Inc. (Wi2) and ChemDiv Research Institute have signed an MOU to form a non-exclusive consortium developing innovative therapeutics aimed at improvement of human and animal health.
The aim of the consortium is to jointly develop and market molecules, biological materials, medical devices, diagnostics, and other technologies and data resulting from Wi2, BPCN@MIPT and ChemDiv technologies.
As quoted in the press release:
Wi2 is a one of a kind non-profit organization formed to facilitate the translation of innovations into applied uses. The work of Wi2 is done in collaboration with the private sector, the University of Wisconsin-Madison, and other institutions nationally and internationally.
Read the full MarketWired press release here
